Loading…
← CockpitCompetitor Analysis › 1952.HK Everest Medicines Ltd.Open in the cockpit ↗

Everest Medicines Ltd.1952.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major

Chinese biopharma that in-licenses innovative drugs in nephrology, infectious disease and oncology for Greater China/Asia.

≈ A Chinese in-licensing specialty pharma, similar to a smaller Zai LabMomentum neutral 46
Mkt cap
$1.05B
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$17.0M
20-day average traded
Fwd P/E
23.2×
forward earnings
ROIC−WACC
-16.1 pp
WACC 14.1%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · HKDHK$24.44
1D-2.2%
1W-9.1%
1M-27.7%
3M+2.7%
6M-20.3%
YTD-33.9%
1Y-46.8%
ATR %7.2%
52w lowhigh51.4% off high

What Everest Medicines does

Chinese biopharma that in-licenses innovative drugs in nephrology, infectious disease and oncology for Greater China/Asia.

Pays licensors upfront fees, milestones and royalties for Greater China and some Asian rights, then earns from selling the drugs itself to hospitals, with Nefecon, a kidney-disease drug licensed from Calliditas, as the lead product. Each market's approvals and reimbursement listings set the volumes.

In one line: A Chinese in-licensing specialty pharma, similar to a smaller Zai Lab.

Products and services

  • Nefecon (nephrology, licensed)
  • Antibiotic/anti-infective drugs
  • Oncology pipeline

Customers

  • Hospitals in China and Asia
  • Global pharma licensors

Where it sits in the supply chain

  • Biotechnology
  • In-licensed drug development
  • Nephrology/infectious disease/oncology

What could go right

  • Nefecon and pipeline launches across Asia

What could go wrong

  • Dependent on licensors' IP
  • Clinical/regulatory risk

Moat: narrow (regulatory licence, distribution). Regional development and commercialization rights secured via licensing deals with global biotechs.

Headquarters: Shanghai, China · Founded: 2017 · Employees: 812

Named competitors

Everest Medicines at a glance

Size Everest Medicines (1952.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $1.05B, the 574th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$24.44 on 18 Nov 2026.

Performance Over six months the shares fell 20.3%, against -8.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 192.6% over the last twelve months (peer median +2.4%); the operating margin is -5.3% (peer median 9.7%).

Valuation It trades at 23.2× forward earnings against a peer median of 14.5× (4th most expensive of 15).

Capital Return on invested capital runs 16.1 points below its cost of capital (14.1% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 931952.HK 77
Six months, rebased to 100: Everest Medicines against the median of its 20 peers (local-currency closes).

Everest Medicines financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$2.69BHK$1.85BHK$766MHK$139MHK$14.9M
Revenue growth—+142%+451%+835%—
Gross profitHK$1.69BHK$1.11BHK$426MHK$16.3M-HK$40.3M
EBITDAHK$40.7M-HK$249M-HK$681M-HK$849M-HK$1.58B
Net income-HK$59.3M-HK$323M-HK$1.13B-HK$933M-HK$288M
Free cash flow-HK$354M-HK$192M-HK$829M-HK$988M-HK$1.76B
Capital expenditureHK$892MHK$378MHK$221MHK$294MHK$503M
Total debtn/aHK$1.03BHK$612MHK$593MHK$124M

Quarterly statements and history in the cockpit →

Everest Medicines competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-20%-10%0%BLUEJET600789BSLNSVRA0027374553688513300497OMER600812300702MEDCL000650PYC4887VETO6880916051163001196887101952.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Everest Medicines is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%20×40×60×BLUEJETBSLN00273745536885133004973007020006506051166887101952.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Everest Medicines is the large dot.

Everest Medicines competitors and peer comparison

Head to head with its named competitors (1952.HK vs ZLAB vs 0867.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Everest Medicines 1952.HK$1.05B-20%+193%-5%23.2×n/a
Zai Lab Ltd. Sponsored ADR ZLAB$3.00B+18%0%-63%n/an/a
China Medical System 0867.HK$2.95B-15%+15%20%9.8×1.1%

How Everest Medicines compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Everest Medicines against its 20 peers (data as of 18 Nov 2026)
Measure1952.HKPeer medianRank in peer set
1-month return-27.7%-4.7%lowest of 21
6-month return-20.3%-8.7%5th lowest of 21
Distance from 52-week high-51.4%-31.7%3rd lowest of 21
Revenue growth (TTM)+192.6%+2.4%highest of 18
Operating margin-5.3%9.7%4th lowest of 19
Forward P/E23.2×14.5×4th most expensive of 15
ROIC minus cost of capital-16.1 pp+0.2 pp3rd lowest of 19
Net debt / EBITDA-1.3×-1.4×3rd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%23.2×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%30.6×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%n/a2.5%+6.5%
Basilea Pharmaceutica BSLN.SWSwitzerland$1.04B+33%+5%24%10.5×-5.6%+12.7%
Savara SVRAUnited States$1.04B-7%n/an/an/an/an/a
Sunflower Pharmaceutical 002737.SZChina$1.04B-11%+31%-7%4.7×-6.5%-7.7%
Towa Pharmaceutical 4553.TJapan$1.03B-10%+7%9%7.7×-0.3%+12.1%
Chengdu Easton Biopharmaceuticals 688513.SSChina$1.03B-33%-2%13%24.6×4.4%+7.7%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Omeros OMERUnited States$1.08B+24%n/a-56%4.3×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%n/a1.0%-4.2%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%n/an/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%15.5×-3.6%+4.2%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%18.1×4.9%+11.3%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%

Questions

Who are Everest Medicines's main competitors?
Named competitors: Zai Lab (ZLAB), BeiGene (private or unlisted), China Medical System (0867.HK). The cockpit's measured peer set (industry) also includes Blue Jet Healthcare (BLUEJET.NS), Shandong Lukang Pharmaceutical (600789.SS), Basilea Pharmaceutica (BSLN.SW), Savara (SVRA), Sunflower Pharmaceutical (002737.SZ), Towa Pharmaceutical (4553.T).
Is Everest Medicines expensive compared with its peers?
On forward p/e it trades at 23.2× against a peer median of 14.5×, 4th most expensive of 15 in its peer set.
How has Everest Medicines stock performed?
Over six months to 18 Nov 2026 the shares returned -20.3% against -8.7% for the median peer; over one year -46.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.